What the Latest Research Shows About Omnipod 5 for Type 1 Diabetes

The Omnipod 5 is an automated insulin delivery system, also called a hybrid closed-loop system. It combines three parts: a small patch pump (called the pod) that holds insulin, a continuous glucose monitor that tracks blood sugar in real time, and software that automatically adjusts insulin delivery based on glucose readings.

The pod is worn directly on the body and needs to be changed every three days. Unlike older insulin pump models, Omnipod 5 users don't need to wear a separate controller device—it connects to a smartphone or compatible device.

Users can customize their glucose targets within a range of 110–150 mg/dL in 10 mg/dL increments, depending on their needs and preferences.

A 2024 study published in Diabetes Technology & Therapeutics examined data from 69,902 people with type 1 diabetes using Omnipod 5 in the United States. This real-world evidence shows how the system performs outside controlled clinical trials.

The results show that glucose control improved with lower target settings. Users targeting 110 mg/dL achieved a median time in range (glucose between 70–180 mg/dL) of 68.8%. Those targeting 120 mg/dL reached 61.3%, and those targeting 130–150 mg/dL achieved 53.6%.

Importantly, time below 70 mg/dL was minimal across all groups (less than 1.13%), showing that lower glucose targets did not significantly increase low blood sugar events. Among users targeting 110 mg/dL, children and adolescents achieved 65.0% time in range, while adults reached 69.9%.

The study also examined people who switched from other insulin delivery methods, including older Omnipod versions and multiple daily injections, and found that Omnipod 5 improved outcomes across different starting points.

A 2024 network meta-analysis compared seven different hybrid closed-loop systems across 28 clinical trials. The analysis ranked the systems by their effectiveness at keeping glucose in range.

The Minimed 780G achieved the highest time in range overall, followed by Control-IQ and then Omnipod 5. However, all hybrid closed-loop systems significantly improved glucose control compared to traditional insulin therapy without continuous glucose monitoring.

All systems—including Omnipod 5—successfully reduced dangerous low blood sugar events. Safety outcomes, including severe low blood sugar and diabetic ketoacidosis, were similar across different systems and comparable to standard insulin therapy.

Research is expanding to examine hybrid closed-loop systems in specific populations. A 2023 study published in the New England Journal of Medicine tested hybrid closed-loop therapy in pregnant women with type 1 diabetes, a group requiring especially tight glucose control. Women using closed-loop therapy spent 68.2% of the time in pregnancy-specific glucose targets compared to 55.6% with standard care.

Clinical experience and case studies are now being documented to help healthcare providers personalize Omnipod 5 settings for individual needs and optimize glucose outcomes in complex medical situations. Researchers are also planning long-term studies to understand the full impact of starting automated insulin delivery early in childhood.

Automated insulin delivery systems like Omnipod 5 are now strongly recommended as a preferred method for managing type 1 diabetes. The real-world evidence shows the system works well across different ages, backgrounds, and previous treatment methods.

Your specific glucose targets and settings will be personalized with your healthcare team based on your individual goals and circumstances. The data suggests that working toward lower targets (when safe for you) may improve your overall glucose control, but this is a conversation to have with your diabetes care provider.

If you're considering Omnipod 5 or any automated insulin delivery system, discuss with your healthcare team whether it fits your lifestyle, insurance coverage, and medical needs.

Origin: YouTube / Jen Grieves (Video report). Evidence: Video report, corroborated with 6 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.